Impact BioMedical, INC. (IBO) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $108.00K; Additional Paid in CapitalUSD $63.15M; Retained Earnings (Accumulated Deficit)USD $-52.49M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $108.00K; Additional Paid in CapitalUSD $63.15M; Retained Earnings (Accumulated Deficit)USD $-51.79M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $105.00K; Additional Paid in CapitalUSD $61.71M; Retained Earnings (Accumulated Deficit)USD $-49.51M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $60.00K; Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $42.87M; Retained Earnings (Accumulated Deficit)USD $-54.75M.
Impact BioMedical, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $108.00K | $63.15M | $-52.49M | $10.77M | $14.01M | (m) | (m) |
| 2026-03-31 | (m) | $108.00K | $63.15M | $-51.79M | $11.46M | $14.71M | (m) | (m) |
| 2025-12-31 | (m) | $105.00K | $61.71M | $-49.51M | $12.31M | $15.55M | 12 month · $13.00K | (m) |
| 2025-09-30 | $60.00K | $12.00K | $42.87M | $-54.75M | $-11.81M | $-8.85M | 9 month · $5.00K | (m) |
| 2025-06-30 | $60.00K | $12.00K | $42.87M | $-53.28M | $-10.34M | $-7.38M | 6 month · $4.00K | (m) |
| 2025-03-31 | $60.00K | $12.00K | $42.71M | $-38.94M | $3.84M | $6.81M | (m) | (m) |
| 2024-12-31 | $60.00K | $11.00K | $41.86M | $-37.67M | $4.26M | $7.24M | 12 month · $19.00K | (m) |
| 2024-09-30 | $60.00K | $11.00K | $41.84M | $-10.56M | $31.35M | $34.35M | (m) | (m) |
| 2024-06-30 | $60.00K | $10.00K | $38.11M | $-14.81M | $23.37M | $26.38M | (m) | (m) |
| 2024-03-31 | $60.00K | $10.00K | $38.11M | $-13.92M | $24.26M | $27.26M | (m) | (m) |
| 2023-12-31 | $60.00K | $10.00K | $38.11M | $-12.96M | $25.22M | $28.26M | (m) | $38.11M |
| 2023-09-30 | (m) | $70.00K | (m) | $-11.67M | $26.52M | $29.58M | (m) | $38.11M |
| 2023-06-30 | (m) | $125.00K | (m) | $-10.56M | $27.62M | $30.70M | (m) | $38.06M |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $31.82M | (m) | (m) |
| 2022-12-31 | (m) | $70.00K | (m) | $-8.62M | $29.56M | $32.67M | (m) | $38.11M |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $36.03M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $38.38M | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | $39.92M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |